Towards mRNA therapeutics 2.0

Kallen, K.-J. et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines. Hum. Vaccin. Immunother. 9, 2263–2276 (2013).

Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

Hogan, M. J. & Pardi, N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu. Rev. Med. 73, 17–39 (2022).

Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vacc. Immunother. 17, 1248–1261 (2021).

Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233–2244 (2023).

Shaw, C. A. et al. Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults. J. Infect. Dis. 230, e647–e656 (2024).

Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899–904 (2022).

Lee, I. T. et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).

Hu, X. et al. Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB/MF59 vaccine. J. Infect. Dis. 230, 455–466 (2024).

Wu, K. et al. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults. J. Virol. 98, e01603-23 (2024).

Fierro, C. et al. Safety and immunogenicity of a messenger RNA-based cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial. J. Infect. Dis. 230, e668–e678 (2024).

Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192–1204 (2024).

Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586–1600 (2022).

Metkar, M., Pepin, C. S. & Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug. Discov. 23, 67–83 (2024).

Tsuchida, C. A., Wasko, K. M., Hamilton, J. R. & Doudna, J. A. Targeted nonviral delivery of genome editors in vivo. Proc. Natl Acad. Sci. USA 121, e2307796121 (2024).

Mendonça, M. C. P., Kont, A., Kowalski, P. S. & O’Driscoll, C. M. Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids. Drug Discov. Today 28, 103505 (2023).

Yuan, Y. et al. Intelligent design of lipid nanoparticles for enhanced gene therapeutics. Mol. Pharm. https://doi.org/10.1021/acs.molpharmaceut.4c00925 (2025).

Dolgin, E. The tangled history of mRNA vaccines. Nature 597, 318–324 (2021).

Shi, Y., Shi, M., Wang, Y. & You, J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Sig Transduct. Target. Ther. 9, 1–43 (2024).

Fuller, D. H. & Berglund, P. Amplifying RNA vaccine development. N. Engl. J. Med. 382, 2469–2471 (2020).

Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261–279 (2018).

Gote, V. et al. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).

Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Primers 3, 1–19 (2023).

Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).

Gómez-Aguado, I. et al. mRNA delivery technologies: toward clinical translation. Int. Rev. Cell Mol. Biol. 372, 207–293 (2022).

Ige, M. A. et al. mRNA therapeutics: transforming medicine through innovation in design, delivery, and disease treatment. Mol. Ther. Nucleic Acids 36, 102721 (2025).

Sonenberg, N. & Gingras, A.-C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10, 268–275 (1998).

Grudzien, E. et al. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 10, 1479–1487 (2004).

Li, Y. & Kiledjian, M. Regulation of mRNA decapping. WIREs RNA 1, 253–265 (2010).

Ziemniak, M., Strenkowska, M., Kowalska, J. & Jemielity, J. Potential therapeutic applications of RNA cap analogs. Future Med. Chem. 5, 1141–1172 (2013).

Mandell, Z. F. et al. CleanCap M6 inhibits decapping of exogenously delivered IVT mRNA. Mol. Ther. Nucleic Acids 36, 102456 (2025).

Inagaki, M. et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat. Commun. 14, 2657 (2023).

Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E. & Rhoads, R. E. Synthesis and properties of mRNAs containing the novel ‘anti-reverse’ cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG. RNA 7, 1486–1495 (2001).

Henderson, J. M. et al. Cap 1 Messenger RNA synthesis with co-transcriptional CleanCap® analog by in vitro transcription. Curr. Protoc. 1, e39 (2021).

Mockey, M. et al. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with poly(A) chains in cis and in trans for a high protein expression level. Biochem. Biophys. Res. Commun. 340, 1062–1068 (2006).

Casmil, I. C. et al. The advent of clinical self-amplifying RNA vaccines. Mol. Ther. 33, 2565–2582 (2025).

Jia, L. et al. Decoding mRNA translatability and stability from the 5′ UTR. Nat. Struct. Mol. Biol. 27, 814–821 (2020).

Sample, P. J. et al. Human 5′ UTR design and variant effect prediction from a massively parallel translation assay. Nat. Biotechnol. 37, 803–809 (2019).

Barazandeh, S., Ozden, F., Hincer, A., Seker, U. O. S. & Cicek, A. E. UTRGAN: learning to generate 5′ UTR sequences for optimized translation efficiency and gene expression. Bioinforma. Adv. 5, vbaf134 (2024).

Yang, Y. et al. Deciphering 3′UTR mediated gene regulation using interpretable deep representation learning. Adv. Sci. 11, e2407013 (2024).

Morrow, A. K. et al. ML-driven design of 3′ UTRs for mRNA stability. Preprint at bioRxiv https://doi.org/10.1101/2024.10.07.616676 (2024).

Orlandini Von Niessen, A. G. et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening. Mol. Ther. 27, 824–836 (2019).

Ma, X. et al. Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3′ UTR via HuR anchorage. Mol. Ther. Nucleic Acids 36, 102485 (2025).

Sultana, N. et al. Optimization of 5′ untranslated region of modified mRNA for use in cardiac or hepatic ischemic injury. Mol. Ther. Methods Clin. Dev. 17, 622–633 (2020).

Li, Y. et al. Deep generative optimization of mRNA codon sequences for enhanced mRNA translation and therapeutic efficacy. Nat. Commun. 16, 9957 (2025).

Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396–403 (2023).

Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).

Hanson, G. & Coller, J. Codon optimality, bias and usage in translation and mRNA decay. Nat. Rev. Mol. Cell Biol. 19, 20–30 (2018).

Narula, A., Ellis, J., Taliaferro, J. M. & Rissland, O. S. Coding regions affect mRNA stability in human cells. RNA 25, 1751–1764 (2019).

Karikó, K. Modified uridines are the key to a successful message. Nat. Rev. Immunol. 21, 619–619 (2021).

Karikó, K. et al. Incorporation of pseudouridine Into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).

Nance, K. D. & Meier, J. L. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 7, 748–756 (2021).

Schrum, J. P., Siddiqi, S. & Ejebe, K. Ribonucleic acids containing N1-methyl-pseudouracils and uses thereof. European Patent EP2622064B1 (18 May 2022).

Li, S. et al. CodonBERT large language model for mRNA vaccines. Genome Res. 34, 1027–1035 (2024).

De Almeida, B. P. et al. A multimodal conversational agent for DNA, RNA and protein tasks. Nat. Mach. Intell. 7, 928–941 (2025).

Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456–1464 (2015).

Biziaev, N. et al. The impact of mRNA poly(A) tail length on eukaryotic translation stages. Nucleic Acids Res. 52, 7792–7808 (2024).

Stowell, J. A. W. et al. Reconstitution of targeted deadenylation by the Ccr4-Not complex and the YTH domain protein Mmi1. Cell Rep. 17, 1978–1989 (2016).

Passmore, L. A. & Coller, J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat. Rev. Mol. Cell Biol. 23, 93–106 (2022).

Xiang, K. & Bartel, D. P. The molecular basis of coupling between poly(A)-tail length and translational efficiency. eLife 10, e66493 (2021).

Grier, A. E. et al. pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences. Mol. Ther. Nucleic Acids 5, e306 (2016).

Chen, H. et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat. Biotechnol. 43, 194–203 (2025).

Aditham, A. et al. Chemically modified mocRNAs for highly efficient protein expression in mammalian cells. ACS Chem. Biol. 17, 3352–3366 (2022).

Li, C. Y. et al. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol. Ther. Nucleic Acids 30, 300–310 (2022).

Liu, B. & Pan, T. Building better mRNA for therapeutics. Nat. Biotechnol. 43, 1058–1060 (2025).

Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).

Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).

Schoenmaker, L. et al. mRNA–lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).

Schlake, T., Thess, A., Fotin-Mleczek, M. & Kallen, K.-J. Developing mRNA-vaccine technologies. RNA Biol. 9, 1319–1330 (2012).

Hou, X., Shi, J. & Xiao, Y. mRNA medicine: recent progresses in chemical modification, design, and engineering. Nano Res. 17, 9015–9030 (2024).

Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282–300 (2023).

Dowdy, S. F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 35, 222–229 (2017).

Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).

Nie, Q. et al. Pathologically triggered in situ aggregation of nanoparticles for inflammation-targeting amplification and therapeutic potentiation. Acta Pharm. Sin. B 13, 390–409 (2023).

Romero, E. L., Morilla, M.-J., Regts, J., Koning, G. A. & Scherphof, G. L. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 448, 193–196 (1999).

Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021).

Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug. Discov. 23, 709–722 (2024).

Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).

Chaudhary, N. et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat. Biomed. Eng. 8, 1483–1498 (2024).

Lui, K. O. et al. Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res. 23, 1172–1186 (2013).

Xie, C., Yao, R. & Xia, X. The advances of adjuvants in mRNA vaccines. npj Vaccines 8, 162 (2023).

Warne, N. et al. Delivering 3 billion doses of Comirnaty in 2021. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01643-1 (2023).

Almquist, J. et al. Model-based analysis reveals a sustained and dose-dependent acceleration of wound healing by VEGF-A mRNA (AZD8601). CPT Pharmacom Syst. Pharma 9, 384–394 (2020).

Carlsson, L. et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine. Mol. Ther. Methods Clin. Dev. 9, 330–346 (2018).

Lui, K. O., Zangi, L. & Chien, K. R. Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA. Stem Cell Res. 13, 693–704 (2014).

Sun, N. et al. Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing. Sci. Rep. 8, 17509 (2018).

Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898–907 (2013).

Gan, L.-M. et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat. Commun. 10, 871 (2019).

Collén, A. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug Discov. 21, 79–80 (2022).

Anttila, V. et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol. Ther. 31, 866–874 (2023).

Yu, Z. et al. Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia. J. Control. Rel. 310, 103–114 (2019).

Ai, X. et al. Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI. Mol. Ther. 31, 211–229 (2023).

Engel, J. E., Williams, E., Williams, M. L., Bidwell, G. L. & Chade, A. R. Targeted VEGF (vascular endothelial growth factor) therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization. Hypertension 74, 1113–1123 (2019).

Geng, Y. et al. BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways. Commun. Biol. 4, 82 (2021).

Yu, F. et al. Human adipose-derived stem cells enriched with VEGF-modified mRNA promote angiogenesis and long-term graft survival in a fat graft transplantation model. Stem Cell Res. Ther. 11, 490 (2020).

Liric Rajlic, I. et al. Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2. CPT Pharmacom Syst. Pharma 13, 1067–1078 (2024).

Lykhopiy, V., Malviya, V., Humblet-Baron, S. & Schlenner, S. M. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity. Genes. Immun. 24, 248–262 (2023).

Raeber, M. E., Sahin, D., Karakus, U. & Boyman, O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. eBioMedicine 90, 104539 (2023).

Mikami, N., Kawakami, R. & Sakaguchi, S. New T reg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression. Curr. Opin. Immunol. 67, 36–41 (2020).

Konrad, M. W. et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 50, 2009–2017 (1990).

Wardell, C. M., Boardman, D. A. & Levings, M. K. Harnessing the biology of regulatory T cells to treat disease. Nat. Rev. Drug. Discov. 24, 93–111 (2025).

De Picciotto, S. et al. Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein. Nat. Commun. 13, 3866 (2022).

Zeng, J. et al. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4. Oncogene 43, 2244–2252 (2024).

Chung, E. et al. Abstract 1368: Novel mRNA encoding anti-PD-L1 monoclonal antibodies for cancer immunotherapy. Cancer Res. 84, 1368 (2024).

Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).

Stadler, C. R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23, 815–817 (2017).

De Vlieger, D. et al. Selective engagement of FcγRIV by a M2e-specific single domain antibody construct protects against influenza A virus infection. Front. Immunol. 10, 2920 (2019).

Van Hoecke, L. et al. mRNA encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol. Ther. Nucleic Acids 20, 777–787 (2020).

Yap, T. A. et al. First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors. J. Clin. Oncol. 43, 2501 (2025).

Aboul-Ella, H. et al. Monoclonal antibodies: from magic bullet to precision weapon. Mol. Biomed. 5, 47 (2024).

Zhao, Y., Gan, L., Ke, D., Chen, Q. & Fu, Y. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. J. Transl. Med. 21, 693 (2023).

Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019).

August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224–2233 (2021).

Hennigan, J. N. & Lynch, M. D. The past, present, and future of enzyme-based therapies. Drug. Discov. Today 27, 117–133 (2022).

Vavilis, T. et al. mRNA in the context of protein replacement therapy. Pharmaceutics 15, 166 (2023).

Byrne, B. J. et al. Current clinical applications of AAV-mediated gene therapy. Mol. Ther. 33, 2479–2516 (2025).

Brunetti-Pierri, N. & Lee, B. Gene therapy for inborn errors of liver metabolism. Mol. Genet. Metab. 86, 13–24 (2005).

Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465–1468 (1990).

Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. & Bloom, F. E. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255, 996–998 (1992).

Koeberl, D. et al. Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature 628, 872–877 (2024).

Chandler, R. J. et al. Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 23, 1252–1261 (2009).

Head, P. E., Meier, J. L. & Venditti, C. P. New insights into the pathophysiology of methylmalonic acidemia. J. Inher Metab. Disea 46, 436–449 (2023).

Fenton, W. A., Gravel, R. A. & Rosenblatt, D. S. Disorders of propionate and methylmalonate metabolism. In The Online Metabolic and Molecular Bases of Inherited Disease (eds Valle, D. L. et al.) Ch. 94 (McGraw-Hill Education, 2019).

Svitkin, Y. V. et al. N1-Methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 45, 6023–6036 (2017).

Desmet, C. J. & Ishii, K. J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunol. 12, 479–491 (2012).

Coughlan, K. A. et al. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy. Mol. Genet. Metab. 143, 108560 (2024).

Marion, R. W. & Paljevic, E. The glycogen storage disorders. Pediatr. Rev. 41, 41–44 (2020).

Derks, T. G. J. et al. Glycogen storage disease type Ia: current management options, burden and unmet needs. Nutrients 13, 3828 (2021).

Wright, T. L. F., Umaña, L. A. & Ramirez, C. M. Update on glycogen storage disease: primary hepatic involvement. Curr. Opin. Pediatr. 34, 496–502 (2022).

Kishnani, P. S., Sun, B. & Koeberl, D. D. Gene therapy for glycogen storage diseases. Hum. Mol. Genet. 28, R31–R41 (2019).

Mitchell, J. et al. Efficacy and safety results from a pivotal phase 3 trial of DTX401, an AAV8-mediated liver-directed gene therapy, in individuals with glycogen storage disease type Ia (GSDIa). Endocrine Abstracts https://doi.org/10.1530/endoabs.110.RC3.6 (2025).

Weinstein, D. A. et al. Safety and efficacy of DTX401, an AAV8-mediated liver-directed gene therapy, in adults with glycogen storage disease type I a (GSDIa). J. Inher. Metab. Dis. 48, e70014 (2025).

Roseman, D. S. et al. G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a. Mol. Ther. 26, 814–821 (2018).

Cao, J. et al. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat. Commun. 12, 3090 (2021).

Cunningham, S. C., Dane, A. P., Spinoulas, A. & Alexander, I. E. Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol. Ther. 16, 1081–1088 (2008).

Yiu, W. H. et al. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol. Ther. 18, 1076–1084 (2010).

Weber, T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front. Immunol. 12, 658399 (2021).

Arnaoutova, I. et al. Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia. Nat. Commun. 15, 9729 (2024).

Okechuku, G. O. et al. Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy. J. Inher. Metab. Dis. 40, 703–708 (2017).

Beegle, R. D., Brown, L. M. & Weinstein, D. A. Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. In JIMD Reports, Vol. 18 (eds Zschocke, J. et al.) (Springer, 2014).

Dambska, M., Labrador, E., Kuo, C. & Weinstein, D. Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control: Dambska et al. Pediatr. Diabetes 18, 327–331 (2017).

Gómez-Aguado, I. et al. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials 10, 364 (2020).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04416126 (2023).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06488313 (2025).

Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534 (2020).

Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).

Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D. & Chan, W. C. W. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Rel. 240, 332–348 (2016).

Lam, K. et al. Optimizing lipid nanoparticles for delivery in primates. Adv. Mater. 35, e2211420 (2023).

Han, X. et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. Nat. Biomed. Eng. 8, 1412–1424 (2024).

Wang, W. et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nat. Commun. 15, 10804 (2024).

Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).

Böttger, R. et al. Lipid-based nanoparticle technologies for liver targeting. Adv. Drug. Delivery Rev. 154–155, 79–101 (2020).

Daly, O. et al. ASL mRNA–LNP therapeutic for the treatment of argininosuccinic aciduria enables survival benefit in a mouse model. Biomedicines 11, 1735 (2023).

Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32, 498 (2009).

Sahin, U., Karikó, K. & Türeci, Ö mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug. Discov. 13, 759–780 (2014).

Mullard, A. COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO. Nat. Rev. Drug. Discov. 20, 500–501 (2021).

Cafri, G. et al. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer. J. Clin. Oncol. 37, 2643–2643 (2019).

Dolgin, E. How personalized cancer vaccines could keep tumours from coming back. Nature 630, 290–292 (2024).

Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).

Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).

Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).

Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619–1629 (2022).

Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014).

Yang, S., Ta, Y.-N. N. & Chen, Y. Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities. Drug. Deliv. Transl. Res. https://doi.org/10.1007/s13346-025-01908-7 (2025).

Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042–1051 (2025).

Sahin, U. et al. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature https://doi.org/10.1038/s41586-025-10004-2 (2026).

Gillmore, J. D. et al. CRISPR–Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493–502 (2021).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04560790 (2022).

Lee, R. G. et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147, 242–253 (2023).

Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).

Kabadi, A. M. et al. AAV-based CRISPR–Cas9 genome editing: challenges and engineering opportunities. Curr. Opin. Biomed. Eng. 29, 100517 (2024).

Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).

Bara-Ledesma, N. et al. Advances in gene therapy for rare diseases: targeting functional haploinsufficiency through AAV and mRNA approaches. Int. J. Mol. Sci. 26, 578 (2025).

Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87–104 (2018).

Villiger, L. et al. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat. Biomed. Eng. 5, 179–189 (2021).

Popovitz, J. et al. Gene editing therapeutics based on mRNA delivery. Adv. Drug. Delivery Rev. 200, 115026 (2023).

Sundararaman, S. S., Döring, Y. & van der Vorst, E. P. C. PCSK9: a multi-faceted protein that is involved in cardiovascular biology. Biomedicines 9, 793 (2021).

Di Taranto, M. D. et al. Identification and in vitro characterization of two new PCSK9 gain of function variants found in patients with familial hypercholesterolemia. Sci. Rep. 7, 15282 (2017).

Sun, H., Krauss, R. M., Chang, J. T. & Teng, B.-B. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. J. Lipid Res. 59, 207–223 (2018).

Katzmann, J. L., Gouni-Berthold, I. & Laufs, U. PCSK9 inhibition: insights from clinical trials and future prospects. Front. Physiol. 11, 595819 (2020).

Kasiewicz, L. N. et al. GalNAc–lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat. Commun. 14, 2776 (2023).

Wan, P. et al. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat. Med. https://doi.org/10.1038/s41591-026-04254-4 (2026).

Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41–51 (2017).

Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2504747 (2025).

Marks, P. Progress in the development of N-of-1 therapy. N. Engl. J. Med. https://doi.org/10.1056/NEJMe2505704 (2025).

Gropman, A. L. & Komor, A. C. Personalized gene editing to treat an inborn error of metabolism. N. Engl. J. Med. https://doi.org/10.1056/NEJMe2505721 (2025).

Summar, M. L. et al. The incidence of urea cycle disorders. Mol. Genet. Metab. 110, 179–180 (2013).

Kido, J., Matsumoto, S., Sugawara, K., Sawada, T. & Nakamura, K. Variants associated with urea cycle disorders in Japanese patients: nationwide study and literature review. Am. J. Med. Genet. Pt A 185, 2026–2036 (2021).

Diorio, C. et al. BEAM-201 for the treatment of relapsed and/or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL): initial data from the phase (Ph) 1/2 dose-exploration, dose-expansion, safety, and efficacy study of multiplex base-edited allogeneic anti-CD7 CAR-T-cells. Blood 144, 4838 (2024).

Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161–177 (2023).

Li, S. et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat. Commun. 13, 5561 (2022).

Zhang, X. et al. Harnessing eukaryotic retroelement proteins for transgene insertion into human safe-harbor loci. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02137-y (2024).

Chen, Y. et al. All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposons. Cell 187, 4674–4689.e18 (2024).

Yarnall, M. T. N. et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat. Biotechnol. 41, 500–512 (2023).

Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436–443 (2023).

Frangoul, H. et al. CRISPR–Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med. 384, 252–260 (2021).

Breda, L. et al. In vivo modification of hematopoietic stem cells by targeted lipid nanoparticles encapsulating mRNA. Blood 140, 305–306 (2022).

Shi, D., Toyonaga, S. & Anderson, D. G. In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Lett. 23, 2938–2944 (2023).

Masson, G. Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders. Fierce Biotech https://www.fiercebiotech.com/biotech/vertex-pays-orna-65m-work-next-gen-gene-therapies-blood-disorders (7 January 2025).

Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409–1417 (2024).

Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926–9937 (2022).

Hofstraat, S. R. J. et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat. Nanotechnol. https://doi.org/10.1038/s41565-024-01847-3 (2025).

Amabile, A. et al. Bispecific antibody targeting of lipid nanoparticles. Preprint at bioRxiv https://doi.org/10.1101/2024.12.20.629467 (2024).

Herrera-Barrera, M. et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci. Adv. 9, eadd4623 (2023).

Han, E. L. et al. Peptide-functionalized lipid nanoparticles for targeted systemic mRNA delivery to the brain. Nano Lett. 25, 800–810 (2025).

Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).

Khorev, O., Stokmaier, D., Schwardt, O., Cutting, B. & Ernst, B. Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg. Med. Chem. 16, 5216–5231 (2008).

Tanowitz, M. et al. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res. 45, 12388–12400 (2017).

Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014).

Melamed, J. R. et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Sci. Adv. 9, eade1444 (2023).

Chen, J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).

Nakamura, T. & Harashima, H. Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy. Adv. Drug. Delivery Rev. 167, 78–88 (2020).

Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35, 752–763 (2021).

Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 22, 578–590 (2023).

Vu, T. et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat. Med. 32, 1131–1141 (2026).

Meister, H. et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clin. Cancer Res. 28, 4747–4756 (2022).

Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844–2853 (2023).

Foster, J. B. et al. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J. Immunother. Cancer 10, e004450 (2022).

Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707–715 (2023).

Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91–96 (2022).

Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533–542 (2022).

Tombácz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA–LNPs. Mol. Ther. 29, 3293–3304 (2021).

Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, 2304378 (2024).

Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311–1317 (2025).

Bae, S.-H. et al. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety. Bioact. Mater. 38, 486–498 (2024).

Nogueira, S. S. et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl. Nano Mater. 3, 10634–10645 (2020).

Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86–93 (2024).

Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjugate Chem. 34, 941–960 (2023).

Bigini, P. et al. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nat. Nanotechnol. 16, 1169–1171 (2021).

Baiersdörfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).

Piao, X. et al. Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA. Mol. Ther. Nucleic Acids 29, 618–624 (2022).

Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J. & Rabideau, A. E. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat. Biotechnol. 41, 560–568 (2023).

Martínez, J., Lampaya, V., Larraga, A., Magallón, H. & Casabona, D. Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction. Front. Mol. Biosci. 10, 1248511 (2023).

Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145–153 (2021).

Liu, Q. et al. Use of a liver-targeting nanoparticle platform to intervene in peanut-induced anaphylaxis through delivery of an Ara h2 T-cell epitope. Nano Today 42, 101370 (2022).

Cao, W. & Xia, T. mRNA lipid nanoparticles induce immune tolerance to treat human diseases. Med. Rev. 3, 180–183 (2021).

Vaidyanathan, S. et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol. Ther. Nucleic Acids 12, 530–542 (2018).

Presnyak, V. et al. Codon optimality is a major determinant of mRNA stability. Cell 160, 1111–1124 (2015).

Boccaletto, P. et al. MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 50, D231–D235 (2022).

Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).

Meulewaeter, S. et al. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J. Control. Rel. 357, 149–160 (2023).

Bogaert, B. et al. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs. J. Control. Rel. 350, 256–270 (2022).

Da Silva Sanchez, A. J. et al. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. J. Control. Rel. 353, 270–277 (2023).

Ning, H. et al. Rational design of microRNA-responsive switch for programmable translational control in mammalian cells. Nat. Commun. 14, 7193 (2023).

Masaki, K., Fujita, Y. & Saito, H. microRNA-responsive ON–OFF hybrid mRNA switch for precise protein expression control. Mol. Ther. Nucleic Acids 36, 102609 (2025).

Abe, I., Ohno, H., Mochizuki, M., Hayashi, K. & Saito, H. Split RNA switch orchestrates pre- and post-translational control to enable cell type-specific gene expression. Nat. Commun. 16, 5362 (2025).

Huang, X. et al. Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease. Sci. Transl. Med. 17, eadu1493 (2025).

Macht, A. et al. Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice. EMBO Rep. 25, 3777–3788 (2024).

Sinegra, A. J., Evangelopoulos, M., Park, J., Huang, Z. & Mirkin, C. A. Lipid nanoparticle spherical nucleic acids for intracellular DNA and RNA delivery. Nano Lett. 21, 6584–6591 (2021).

Semple, S. C., Leone, R., Barbosa, C. J., Tam, Y. K. & Lin, P. J. C. Lipid nanoparticle delivery systems to enable mRNA-based therapeutics. Pharmaceutics 14, 398 (2022).

LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, K. A. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J. Control. Rel. 345, 819–831 (2022).

Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060–2065 (2017).

Kim, H. et al. Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys. Nat. Biotechnol. 43, 1813–1820 (2025).

Haley, R. M. et al. Lipid nanoparticles for in vivo lung delivery of CRISPR–Cas9 ribonucleoproteins allow gene editing of clinical targets. ACS Nano 19, 13790–13804 (2025).

Cappelluti, M. A. et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature 627, 416–423 (2024).

Hennig, M. et al. Inhaled DNAI1 mRNA therapy for treatment of primary ciliary dyskinesia. Proc. Natl Acad. Sci. USA 122, e2421915122 (2025).

Cohn, D. M. et al. CRISPR-based therapy for hereditary angioedema. N. Engl. J. Med. 392, 458–467 (2025).

Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262–272 (2023).

McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).

Pollock, K. M. et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. eClinicalMedicine 44, 101262 (2022).

Trepotec, Z., Geiger, J., Plank, C., Aneja, M. K. & Rudolph, C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA 25, 507–518 (2019).

Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446–455 (2018).

Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06714253 (2026).

Papukashvili, D. et al. Self-amplifying RNA approach for protein replacement therapy. IJMS 23, 12884 (2022).

Ballesteros-Briones, M. C., Silva-Pilipich, N., Herrador-Cañete, G., Vanrell, L. & Smerdou, C. A new generation of vaccines based on alphavirus self-amplifying RNA. Curr. Opin. Virol. 44, 145–153 (2020).

Kim, J., Eygeris, Y., Gupta, M. & Sahay, G. Self-assembled mRNA vaccines. Adv. Drug. Delivery Rev. 170, 83–112 (2021).

Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757–772 (2019).

Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117–129 (2021).

Pepini, T. et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 198, 4012–4024 (2017).

Torkzaban, B. et al. Use of polyadenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders. Mol. Ther. Nucleic Acids 36, 102453 (2025).

Chen, H. et al. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation. Nat. Biotechnol. 43, 1128–1143 (2025).

Jin, L., Zhou, Y., Zhang, S. & Chen, S.-J. mRNA vaccine sequence and structure design and optimization: advances and challenges. J. Biol. Chem. 301, 108015 (2025).

Fu, H. et al. Codon optimization with deep learning to enhance protein expression. Sci. Rep. 10, 17617 (2020).

Constant, D. A. et al. Deep learning-based codon optimization with large-scale synonymous variant datasets enables generalized tunable protein expression. Preprint at bioRxiv https://doi.org/10.1101/2023.02.11.528149 (2023).

Zhang, H. et al. Deep generative models design mRNA sequences with enhanced translational capacity and stability. Science 390, eadr8470 (2025).

Liu, Z. & Dong, Y. AI-powered design accelerates the development of mRNA therapeutics. Nat. Chem. Biol. 22, 15–16 (2026).

Castillo-Hair, S. et al. Optimizing 5′UTRs for mRNA-delivered gene editing using deep learning. Nat. Commun. 15, 5284 (2024).

Liu, Y., Gao, J., Zhang, X. & Fang, X. Joint Design of 5′ Untranslated Region and Coding Sequence of mRNA. Preprint at arXiv https://doi.org/10.48550/arXiv.2410.20781 (2024).

Luna-Cerralbo, D. et al. A statistical-physics approach for codon usage optimisation. Comput. Struct. Biotechnol. J. 23, 3050–3064 (2024).

Madani, A. et al. Large language models generate functional protein sequences across diverse families. Nat. Biotechnol. 41, 1099–1106 (2023).

Wayment-Steele, H. K. et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 49, 10604–10617 (2021).

Vostrosablin, N. et al. mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies. NAR Genom. Bioinform. 6, lqae028 (2024).

Lai, W.-J. C. et al. Intrinsically unstructured sequences in the mRNA 3′ UTR reduce the ability of poly(A) tail to enhance translation. J. Mol. Biol. 434, 167877 (2022).

Haberman, N. et al. Widespread 3′UTR capped RNAs derive from G-rich regions in proximity to AGO2 binding sites. BMC Biol. 22, 254 (2024).

Carbonell-Sala, S. et al. CapTrap-seq: a platform-agnostic and quantitative approach for high-fidelity full-length RNA sequencing. Nat. Commun. 15, 5278 (2024).